Margo Cohen

Last updated
Margo P. Cohen
Alma mater University of Michigan Medical School
University of Buenos Aires
Occupation(s)Physician, entrepreneur
EmployerGlycadia
Known for Diabetes research
TitlePresident and Chief Scientific Officer

Margo Panush Cohen is an American physician and entrepreneur. She has been a Professor of Internal Medicine and Chief of Endocrinology and Metabolism at the Wayne State University School of Medicine and the University of Medicine and Dentistry of New Jersey. She is President and Chief Scientific Officer of Glycadia, and a founder of its subsidiary Exocell.

Contents

Education

Cohen earned a BS from the University of Michigan and an MD from the University of Michigan Medical School. She held an internship at Sinai Hospital in Detroit, Michigan and a residency at Detroit's Henry Ford Hospital. She was then awarded fellowships from the Public Health Service and the National Institutes of Health and pursued doctoral studies in biochemistry at Wayne State University. Moving with her family to Argentina, she completed her doctoral program at the University of Buenos Aires. [1] [2]

Career

Returning from Argentina, Cohen joined the faculty of Wayne State University School of Medicine as Assistant Professor of Medicine, becoming Full Professor and head of Endocrinology and Metabolism at the Medical Center's Detroit Receiving Hospital. [1] In 1982 she became Professor of Medicine and Head of the Division of Endocrinology and Metabolism at the University of Medicine and Dentistry of New Jersey. She received a Fulbright Scholarship in 1986 for a sabbatical in Israel at the Beilinson Hospital/University of Tel Aviv. [1]

Cohen founded Exocell in 1988 to develop diabetes-related diagnostic products, and subsequently established Glycadia to develop therapeutic products. The company received initial financing from venture funds and the Commonwealth of Pennsylvania. Its first FDA-approved diagnostic product was Albuwell, a test that detects diabetic kidney disease, followed by other diagnostic products approved by the U.S. Food and Drug Administration (FDA) to monitor diabetes management and complications. [1] [3] She holds twelve patents in the field of diabetes treatment. [4] She continues to be the President and Chief Scientific Officer of Glycadia, . [5]

Cohen has been editor-in chief- of the Journal Endocrinology and served on study sections of the National Institutes of Health. She was twice appointed Chairman of the Board of Scientific Counselors for the National Institute of Dental Research at the National Institutes of Health. [6] [7] She was elected a member of the American Society for Clinical Investigation in 1982 and is currently[ when? ] an emeritus member of the society. [8]

Research

Cohen has contributed to several areas in endocrine and diabetes research. While in graduate school, she uncovered the mechanism by which the anti-convulsant aminoglutethemide interferes with the production of adrenal steroids, leading to clinical use of the drug in hormone-dependent cancers. [9] [10] In Argentina she studied the effects of diabetes, insulin and pituitary hormones on protein synthesis and vascular metabolism. [11] [12] As a visiting scientist in England, she examined effects of diabetes on basement membranes. [13] In Israel, Cohen discovered the increased prevalence of diabetes in young Ethiopian immigrants and linked it to radical changes in dietary habits. [14] [15] She has also researched immune factors diabetes [16] and the cause of kidney, eye and vascular complications tied to diabetes, uncovering the role of increased nonenzymatic glycation in their genesis and identifying abnormalities in the production of matrix components and in signaling pathways inhibition. [17] [18] [19] [20] [21] [22]

Publishing

Cohen has authored and edited numerous books in the areas of diabetes, endocrinology and metabolism. These include:

  1. Diabetes and Protein Glycosylation: Methods of Measurement and Biologic Relevance; Springer Verlag, New York(1986) ISBN   0-387-96297-2
  2. The Polyol Paradigm and Complications of Diabetes; Springer Verlag, New York (1987) ISBN   0-387-96418-5
  3. Special Topics in Endocrinology and Metabolism; Alan R. Liss, Inc., New York(1979) ISBN   0-8451-0700-3; (1980) ISBN   0-8451-0701-1; (1981) ISBN   0-8451-0702-X; (1982) ISBN   0-8451-0703-8; (1983) ISBN   0-8451-0704-6; (1984) ISBN   0-8451-0705-4; (1985) ISBN   0-8451-0706-2
  4. Endocrinology & Metabolism: Hormone Resistance and Endocrine Paradoxes;Springer Verlag, New York (1987) ISBN   0-387-96517-3
  5. Controversies in Diabetes and Pregnancy; Springer Verlag, New York (1988) ISBN   0-387-96622-6
  6. The Brain as an Endocrine Organ; Springer Verlag, New York(1989) ISBN   0-387-96644-7
  7. Diabetes and Autoimmunity; Springer Verlag, New York (1990) ISBN   0-387-96645-5
  8. Diabetes and Protein Glycation. Clinical and Pathophysiological Relevance;JC Press, Philadelphia(1996) ISBN   0-9654654-0-3

Personal life

Cohen married her college boyfriend, Perry M. Cohen, an investment banker, and she is the mother of three sons:. [1] [23] [24] [25]

Related Research Articles

<span class="mw-page-title-main">Endocrinology</span> Branch of medicine dealing the endocrine system

Endocrinology is a branch of biology and medicine dealing with the endocrine system, its diseases, and its specific secretions known as hormones. It is also concerned with the integration of developmental events proliferation, growth, and differentiation, and the psychological or behavioral activities of metabolism, growth and development, tissue function, sleep, digestion, respiration, excretion, mood, stress, lactation, movement, reproduction, and sensory perception caused by hormones. Specializations include behavioral endocrinology and comparative endocrinology.

<span class="mw-page-title-main">Type 2 diabetes</span> Form of diabetes mellitus

Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, fatigue and unexplained weight loss. Other symptoms include increased hunger, having a sensation of pins and needles, and sores (wounds) that heal slowly. Symptoms often develop slowly. Long-term complications from high blood sugar include heart disease, stroke, diabetic retinopathy, which can result in blindness, kidney failure, and poor blood flow in the lower-limbs, which may lead to amputations. The sudden onset of hyperosmolar hyperglycemic state may occur; however, ketoacidosis is uncommon.

<span class="mw-page-title-main">Cortisol</span> Human natural glucocorticoid hormone

Cortisol is a steroid hormone in the glucocorticoid class of hormones and a stress hormone. When used as medication, it is known as hydrocortisone.

Glycated hemoglobin is a form of hemoglobin (Hb) that is chemically linked to a sugar. 'Glycosylated haemoglobin' is a misnomer, as glycation and glycosylation are different processes, of which only the former is relevant in this case.

Advanced glycation end products (AGEs) are proteins or lipids that become glycated as a result of exposure to sugars. They are a bio-marker implicated in aging and the development, or worsening, of many degenerative diseases, such as diabetes, atherosclerosis, chronic kidney disease, and Alzheimer's disease.

<span class="mw-page-title-main">Diabetic nephropathy</span> Chronic loss of kidney function

Diabetic nephropathy, also known as diabetic kidney disease, is the chronic loss of kidney function occurring in those with diabetes mellitus. Diabetic nephropathy is the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD) globally. The triad of protein leaking into the urine, rising blood pressure with hypertension and then falling renal function is common to many forms of CKD. Protein loss in the urine due to damage of the glomeruli may become massive, and cause a low serum albumin with resulting generalized body swelling (edema) so called nephrotic syndrome. Likewise, the estimated glomerular filtration rate (eGFR) may progressively fall from a normal of over 90 ml/min/1.73m2 to less than 15, at which point the patient is said to have end-stage renal disease. It usually is slowly progressive over years.

11β-Hydroxysteroid dehydrogenase enzymes catalyze the conversion of inert 11 keto-products (cortisone) to active cortisol, or vice versa, thus regulating the access of glucocorticoids to the steroid receptors.

<span class="mw-page-title-main">Human serum albumin</span> Albumin found in human blood

Human serum albumin is the serum albumin found in human blood. It is the most abundant protein in human blood plasma; it constitutes about half of serum protein. It is produced in the liver. It is soluble in water, and it is monomeric.

<span class="mw-page-title-main">Dehydroepiandrosterone sulfate</span> Chemical compound

Dehydroepiandrosterone sulfate, abbreviated as DHEA sulfate or DHEA-S, also known as androstenolone sulfate, is an endogenous androstane steroid that is produced by the adrenal cortex. It is the 3β-sulfate ester and a metabolite of dehydroepiandrosterone (DHEA) and circulates in far greater relative concentrations than DHEA. The steroid is hormonally inert and is instead an important neurosteroid and neurotrophin.

<span class="mw-page-title-main">Endocrine disease</span> Disorders of the endocrine system

Endocrine diseases are disorders of the endocrine system. The branch of medicine associated with endocrine disorders is known as endocrinology.

<span class="mw-page-title-main">Dapagliflozin</span> Diabetes medication

Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. It reversibly inhibits sodium-glucose co-transporter 2 (SGLT-2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

<span class="mw-page-title-main">Diabetic cardiomyopathy</span> Medical condition

Diabetic cardiomyopathy is a disorder of the heart muscle in people with diabetes. It can lead to inability of the heart to circulate blood through the body effectively, a state known as heart failure(HF), with accumulation of fluid in the lungs or legs. Most heart failure in people with diabetes results from coronary artery disease, and diabetic cardiomyopathy is only said to exist if there is no coronary artery disease to explain the heart muscle disorder.

Derek LeRoith is a South African endocrinologist and Professor of Medicine and the current Chief of the Hilda and J. Lester Gabrilove, M.D. Division of Endocrinology, Diabetes and Bone Disease and Director of the Metabolism Institute of the Mount Sinai Medical Center in New York City. He is an international expert in insulin-like growth factor-1 (IGF-1).

<span class="mw-page-title-main">3-Deoxyglucosone</span> Chemical compound

3-Deoxyglucosone (3DG) is a sugar that is notable because it is a marker for diabetes. 3DG reacts with protein to form advanced glycation end-products (AGEs), which contribute to diseases such as the vascular complications of diabetes, atherosclerosis, hypertension, Alzheimer's disease, inflammation, and aging.

Empagliflozin, sold under the brand name Jardiance, among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes. It is taken by mouth.

<span class="mw-page-title-main">Leonid Poretsky</span> American endocrinologist

Leonid Poretsky is a Russian-born American endocrinologist. His research interests include mechanisms of insulin action in the ovary, endocrinological aspects of AIDS, and clinical outcomes in diabetes. He has authored over 150 publications and has served on the National Institutes of Health's review committees and on the editorial boards of the Journal of Clinical Endocrinology and Metabolism and other endocrine journals.

Mladen Vranic, MD, DSc, O.C., O.Ont, FRSC, FRCP(C), FCAHS, Canadian Medical Hall of Fame[CMHF] April 3, 1930 – June 18, 2019, was a Croatian-born diabetes researcher, best known for his work in tracer methodology, exercise and stress in diabetes, the metabolic effects of hormonal interactions, glucagon physiology, extrapancreatic glucagon, the role of the direct and indirect metabolic effects of insulin and the prevention of hypoglycemia. Vranic was recognized by a number of national and international awards for his research contributions, mentoring and administration including the Orders of Canada (Officer) and Ontario.

<span class="mw-page-title-main">Amphenone B</span> Chemical compound

Amphenone B, or simply amphenone, also known as 3,3-bis(p-aminophenyl)butan-2-one, is an inhibitor of steroid hormone and thyroid hormone biosynthesis which was never marketed but has been used as a tool in scientific research to study corticosteroids and the adrenal glands. It acts as competitive inhibitor of 11β-hydroxylase, 17α-hydroxylase, 17,20-lyase, 21-hydroxylase, and 3β-hydroxysteroid dehydrogenase, as well as of cholesterol side-chain cleavage enzyme, thereby inhibiting the production of steroid hormones including glucocorticoids, mineralocorticoids, androgens, and estrogens. In addition, amphenone B inhibits the production of thyroxine by a thiouracil-like mechanism, specifically via inhibition of organic binding of iodine and uptake of iodide by the thyroid gland.

Allen Lein was an endocrinologist and medical school professor. He was a Guggenheim Fellow for the academic year 1958–1959.

<span class="mw-page-title-main">Adolf Magnus-Levy</span> German-American physician and physiologist

Adolf Magnus-Levy was a German physician and physiologist who studied human metabolism and diseases associated with it. He took a special interest in studies of diabetes, goitre, and myeloma. Being of Jewish origin, he escaped Nazi persecution and became a citizen of the United States of America in 1940 and served as a professor at Yale University.

References

  1. 1 2 3 4 5 Valerie Reitman (February 20, 1989). "A Doctor Gets Down To Business". Philadelphia Inquirer . Archived from the original on March 4, 2016.
  2. ↑ "Margo Cohen". Archived from the original on September 13, 2017. Retrieved February 25, 2014.
  3. ↑ "Brotherly Love, Cheese Steaks And Biomed?". Businessweek. March 3, 1991. Archived from the original on March 19, 2014. Retrieved September 24, 2013.
  4. ↑ "Margo P Cohen - Inventor". Archived from the original on November 18, 2018. Retrieved September 24, 2013.
  5. ↑ "Patent Application Titled "Long-Acting and Controlled Release Formulations of 2-[(3-Chlorophenyl) Amino] Phenylacetic Acid" Published Online". Diabetes Week. February 17, 2014. Archived from the original on June 11, 2014. Retrieved March 19, 2014.
  6. ↑ Richard Stone (May 21, 1993). "Dental Institute Report Has NIH Down in the Mouth". Science . 260 (5111): 1069. Bibcode:1993Sci...260.1069S. doi:10.1126/science.8493546. PMID   8493546.
  7. ↑ "Translational Research | Vol 149, Issue 6, Pages A1-A8, 293-356 (June 2007)". Science Direct . Elsevier . Retrieved 2022-08-25.
  8. ↑ "Margo Panush Cohen, MD PhD" . Retrieved October 8, 2013.
  9. ↑ Cash, Ralph; Brough, A. Joseph; Margo, N.P.Cohen; Satoh, Paul S. (1967). "Aminoglutethimide as an inhibitor of adrenal steroidogenesis". J Clin Endocrinol Metab. 27 (9): 1239–1242. doi:10.1210/jcem-27-9-1239. PMID   4292247.
  10. ↑ Cohen, Margo P. (1968). "Aminoglutethimide inhibition of adrenal desmolase activity". Proc Soc Exp Biol Med. 127 (4): 1086–1090. doi:10.3181/00379727-127-32877. PMID   4385282. S2CID   38942051.
  11. ↑ Cohen, Margo P.; Foglia, Virgilio G. (1970). "Aortic mucopolysaccharides in experimental diabetes". Diabetes. 19 (9): 639–643. doi:10.2337/diab.19.9.639. PMID   4248450. S2CID   31726908.
  12. ↑ Cohen, M.P.; Grinblat, L. (1972). "Effect of diabetes on the activity of soluble factors required in ribosomal protein synthesis". Horm Metab Res. 4 (04): 249–253. doi:10.1055/s-0028-1094060. PMID   5086196. S2CID   22160676.
  13. ↑ Margo Cohen; et al. (May 1981). "Nonenzymatic Glycosylation of Basement Membranes" (PDF). Diabetes. 30 (5): 367–371. doi:10.2337/diab.30.5.367. PMID   7227657. S2CID   39313818 . Retrieved September 24, 2013.
  14. ↑ Margo Cohen; et al. (June 1988). "High Prevalence of Diabetes in Young Adult Ethiopian Immigrants to Israel" (PDF). Diabetes. 37 (6): 824–8. doi:10.2337/diab.37.6.824. PMID   3384182. S2CID   27276439.
  15. ↑ C.N. Hales, Fetal nitrition and adult diabetes. Scientific American , Jul-Aug, 1994 pp. 53–54
  16. ↑ Warren Leary (June 19, 1990). "Researchers closing in on a large scale test to screen for diabetes". New York Times .
  17. ↑ Margo Cohen; et al. (October 8, 2001). "Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-bold beta1". Kidney International. 61 (6): 2025–32. doi: 10.1046/j.1523-1755.2002.00352.x . PMID   12028443.
  18. ↑ Margo Cohen; et al. (November 2008). "Amelioration of Diabetes-Associated Abnormalities in the Vitreous Fluid by an Inhibitor of Albumin Glycation". Investigative Ophthalmology & Visual Science. 49 (11): 5089–93. doi: 10.1167/iovs.08-1993 . PMID   18599566.
  19. ↑ Cohen, Margo P.; Shea, Elizabeth; Wu, Van-Yu (2010). "Inhibiting low density lipoprotein glycation ameliorates increased cholesteryl synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in streptozotocin diabetic rats". Metabolism. 59 (5): 658–663. doi:10.1016/j.metabol.2009.09.010. PMC   2856719 . PMID   19922964.
  20. ↑ Kennedy, Laurence; Pilar Solano, Maria; Meneghini, Luigi; Lo, Margaret; Cohen, Margo P. (2010). "Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes". Am J Nephrol. 31 (2): 110–116. doi:10.1159/000259897. PMID   19923796. S2CID   11014059.
  21. ↑ Cohen, Margo P.; Chen, Sheldon; et al. (2005). "Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy". Kidney Int. 68 (4): 1554–1561. doi: 10.1111/j.1523-1755.2005.00567.x . PMID   16164632.
  22. ↑ Margo P. Cohen, Gregory T. Lautenslager et al. "Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and Collagen IV subchain production and the development of renal insufficiency." Amer J Physiology – Renal Physiology 292:F789-F795, 2007
  23. ↑ Michael H. Cohen (2007). Healing at the Borderland of Medicine and Religion. University of North Carolina Press. p. xii. ISBN   9780807877425 . Retrieved September 24, 2013.
  24. ↑ "Nancy Ann Jeffrey Weds Daniel Cohen". New York Times . August 18, 1991. Retrieved September 24, 2013.
  25. ↑ "Perry M. Cohen obituary". Legacy.com . Retrieved March 19, 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.